Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PRPO – Precipio Inc

PRPO — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

0.43

Margin Of Safety %

-7

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

23.76

Target Price

19

Analyst Recom

1

Performance Q

-4.15

Upside

-128.4%

Beta

1.37

Ticker: PRPO




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-04-23PRPO27.05N/AN/A0
2026-04-24PRPO27.995N/AN/A0
2026-04-27PRPO30.8284N/AN/A0
2026-04-28PRPO31.51N/AN/A0
2026-04-29PRPO29.96N/AN/A0
2026-04-30PRPO30.77N/AN/A0
2026-05-01PRPO30.7N/AN/A0
2026-05-04PRPO29.31N/AN/A0
2026-05-05PRPO32.18N/AN/A0
2026-05-06PRPO30.07N/AN/A0
2026-05-07PRPO30.43N/AN/A0
2026-05-08PRPO29.4N/AN/A0
2026-05-11PRPO28.245N/AN/A0
2026-05-12PRPO28.49N/AN/A0
2026-05-13PRPO28.35N/AN/A0
2026-05-14PRPO28.5N/AN/A0
2026-05-15PRPO26.25N/AN/A0
2026-05-18PRPO25.38N/AN/A0
2026-05-19PRPO25.48N/AN/A0
2026-05-20PRPO24.43N/AN/A0
2026-05-21PRPO24.785N/AN/A0
2026-05-22PRPO23.89N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-04-23PRPO27.05- - -
2026-04-24PRPO28.00- - -
2026-04-27PRPO30.81- - -
2026-04-28PRPO31.51- - -
2026-04-30PRPO30.77- - -
2026-05-01PRPO30.80- - -
2026-05-04PRPO29.31- - -
2026-05-05PRPO32.19- - -
2026-05-06PRPO29.70- - -
2026-05-07PRPO30.34- - -
2026-05-08PRPO29.45- - -
2026-05-11PRPO28.36- - -
2026-05-12PRPO28.55- - -
2026-05-13PRPO28.35- - -
2026-05-14PRPO28.33- - -
2026-05-15PRPO26.25- - -
2026-05-18PRPO24.94- - -
2026-05-19PRPO25.48- - -
2026-05-20PRPO24.44- - -
2026-05-21PRPO24.80- - -
2026-05-22PRPO23.76- - -
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-04-23PRPO0.06-4.760.37
2026-04-24PRPO0.06-4.760.37
2026-04-27PRPO0.06-4.760.55
2026-04-28PRPO0.06-4.760.55
2026-04-29PRPO0.06-4.760.55
2026-04-30PRPO0.06-4.760.55
2026-05-01PRPO0.06-4.760.55
2026-05-04PRPO0.06-4.750.55
2026-05-05PRPO0.06-4.750.55
2026-05-06PRPO0.06-4.750.55
2026-05-07PRPO0.06-4.750.55
2026-05-08PRPO0.06-4.750.55
2026-05-11PRPO0.06-3.980.55
2026-05-12PRPO0.06-3.980.43
2026-05-13PRPO0.06-3.980.43
2026-05-14PRPO0.06-3.980.43
2026-05-15PRPO0.06-3.980.43
2026-05-18PRPO0.06-3.970.43
2026-05-19PRPO0.07-3.970.43
2026-05-20PRPO0.07-3.970.43
2026-05-21PRPO-2.09-3.970.43
2026-05-22PRPO-2.09-3.970.43
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

-2.09

Institutional Transactions

-3.97

Beta

1.37

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

22.01

Quality Score

49

Growth Score

52

Sentiment Score

74

Actual DrawDown %

74.5

Max Drawdown 5-Year %

-94.7

Target Price

19

P/E

Forward P/E

PEG

P/S

1.65

P/B

3

P/Free Cash Flow

75.97

EPS

-0.52

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3.57

Relative Volume

0.69

Return on Equity vs Sector %

-33.6

Return on Equity vs Industry %

-17.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

PRPO Healthcare
$23.80
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
6/20
Pullback
15/25
Volume
9/15
Valuation
6/20
TP/AR
2/10
Options
0/10
RSI
35.3
Range 1M
7.7%
🚀
Momentum Growth
Ride accelerating trends
N/A
19 /100
WEAK
Momentum
9/25
Growth
7/30
Estimates
2/20
Inst/Vol
1/15
Options
0/10
EPS Yr
0%
EPS NY
0%
52W%
62.1%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🔴 SELL -12.6% upside
Quality
4/30
Valuation
4/30
Growth
2/25
Stability
5/10
LT Trend
1/5
Upside
-12.6%
Quality
49
MoS
-7%
Precipio, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 61
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
PRPO

Latest News

Caricamento notizie per PRPO
stock quote shares PRPO – Precipio Inc Stock Price stock today
news today PRPO – Precipio Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PRPO – Precipio Inc yahoo finance google finance
stock history PRPO – Precipio Inc invest stock market
stock prices PRPO premarket after hours
ticker PRPO fair value insiders trading

PRPH – ProPhase Labs Inc

PRPH — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

0.54

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

0.13

Target Price

160

Analyst Recom

1

Performance Q

-93.37

Upside

N/A

Beta

-0.54

Ticker: PRPH




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-04-23PRPH0.1198N/AN/A0
2026-04-24PRPH0.1217N/AN/A0
2026-04-27PRPH0.1498N/AN/A0
2026-04-28PRPH0.124N/AN/A0
2026-04-29PRPH0.135N/AN/A0
2026-04-30PRPH0.1307N/AN/A0
2026-05-01PRPH0.135N/AN/A0
2026-05-04PRPH0.1495N/AN/A0
2026-05-05PRPH0.1485N/AN/A0
2026-05-06PRPH0.138N/AN/A0
2026-05-07PRPH0.1298N/AN/A0
2026-05-08PRPH0.1205N/AN/A0
2026-05-11PRPH0.1288N/AN/A0
2026-05-12PRPH0.12N/AN/A0
2026-05-13PRPH0.1196N/AN/A0
2026-05-14PRPH0.1198N/AN/A0
2026-05-15PRPH0.1099N/AN/A0
2026-05-18PRPH0.11N/AN/A0
2026-05-19PRPH0.1022N/AN/A0
2026-05-20PRPH0.0979N/AN/A0
2026-05-21PRPH0.09N/AN/A0
2026-05-22PRPH0.1089N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-04-23PRPH0.12- - -1.55
2026-04-24PRPH0.12- - -1.55
2026-04-27PRPH0.13- - -1.55
2026-04-28PRPH0.14- - -1.55
2026-04-30PRPH0.14- - -1.55
2026-05-01PRPH0.13- - -1.55
2026-05-04PRPH0.14- - -1.55
2026-05-05PRPH0.15- - -1.55
2026-05-06PRPH0.15- - -1.55
2026-05-07PRPH0.14- - -1.55
2026-05-08PRPH0.12- - -1.55
2026-05-11PRPH0.12- - -1.55
2026-05-12PRPH0.13- - -1.55
2026-05-13PRPH0.13- - -1.55
2026-05-14PRPH0.13- - -1.55
2026-05-15PRPH0.13- - -1.55
2026-05-18PRPH0.13- - -1.55
2026-05-19PRPH0.13- - -1.55
2026-05-20PRPH0.13- - -1.55
2026-05-21PRPH0.13- - -1.55
2026-05-22PRPH0.13- - -1.55
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




No data found

Last Quarter Act. EPS

-0.16

Avg. EPS Est. Current Quarter

-0.41

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

-0.54

Average Sales Estimate Current Quarter

4

Average Sales Estimate Next Quarter

Fair Value

Quality Score

20

Growth Score

30

Sentiment Score

53

Actual DrawDown %

99.9

Max Drawdown 5-Year %

-100

Target Price

160

P/E

Forward P/E

PEG

P/S

P/B

0.22

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

-1.55

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

-634.9

Return on Equity vs Industry %

-618.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-1.18

EBIT Estimation

ProPhase Labs, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Employees:
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
PRPH

Latest News

Caricamento notizie per PRPH
stock quote shares PRPH – ProPhase Labs Inc Stock Price stock today
news today PRPH – ProPhase Labs Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PRPH – ProPhase Labs Inc yahoo finance google finance
stock history PRPH – ProPhase Labs Inc invest stock market
stock prices PRPH premarket after hours
ticker PRPH fair value insiders trading

NEO – Neogenomics Inc.

NEO — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

7.46

Margin Of Safety %

Put/Call OI Ratio

0.1

EPS Next Q Diff

0.11

EPS Last/This Y

1.02

EPS This/Next Y

0.18

Price

9.23

Target Price

15.06

Analyst Recom

1.67

Performance Q

-7.42

Upside

-392.0%

Beta

1.79

Ticker: NEO




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-04-23NEO7.920.130.0010992
2026-04-24NEO8.30.130.0010993
2026-04-27NEO8.620.130.1111022
2026-04-28NEO9.020.150.0411218
2026-04-29NEO8.970.160.1210967
2026-04-30NEO9.270.160.1611052
2026-05-01NEO9.440.160.1211072
2026-05-04NEO8.990.160.0611063
2026-05-05NEO8.850.160.0811070
2026-05-06NEO8.890.163.8011047
2026-05-07NEO9.070.160.2911062
2026-05-08NEO8.970.160.0011061
2026-05-11NEO8.650.160.1111070
2026-05-12NEO8.760.160.0011069
2026-05-13NEO8.270.160.1211037
2026-05-14NEO8.360.160.0011073
2026-05-15NEO8.230.150.0311082
2026-05-18NEO8.360.110.005984
2026-05-19NEO8.390.110.045991
2026-05-20NEO8.90.110.006102
2026-05-21NEO9.110.110.006412
2026-05-22NEO9.220.100.016509
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-04-23NEO7.910.0- 0.15
2026-04-24NEO8.290.0- 0.15
2026-04-27NEO8.620.0- 0.15
2026-04-28NEO9.030.0- 0.15
2026-04-30NEO9.270.0- 0.15
2026-05-01NEO9.440.0- 0.17
2026-05-04NEO8.993.7- 0.17
2026-05-05NEO8.853.7- 0.18
2026-05-06NEO8.893.7- 0.18
2026-05-07NEO9.073.7- 0.18
2026-05-08NEO8.973.7- 0.18
2026-05-11NEO8.6512.1- 0.18
2026-05-12NEO8.7612.1- 0.18
2026-05-13NEO8.2612.1- 0.18
2026-05-14NEO8.3512.1- 0.18
2026-05-15NEO8.2412.1- 0.18
2026-05-18NEO8.3612.1- 0.18
2026-05-19NEO8.3812.1- 0.18
2026-05-20NEO8.8912.1- 0.18
2026-05-21NEO9.1112.1- 0.18
2026-05-22NEO9.2312.1- 0.18
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-04-23NEO-1.856.565.97
2026-04-24NEO-1.846.565.95
2026-04-27NEO-1.846.366.17
2026-04-28NEO-1.846.366.17
2026-04-29NEO-1.846.366.17
2026-04-30NEO-1.846.366.17
2026-05-01NEO-1.846.366.16
2026-05-04NEO-1.846.226.16
2026-05-05NEO-1.846.226.16
2026-05-06NEO-1.846.226.16
2026-05-07NEO-1.846.226.16
2026-05-08NEO-1.846.226.16
2026-05-11NEO-1.8410.476.16
2026-05-12NEO-1.8410.477.46
2026-05-13NEO-1.8610.477.46
2026-05-14NEO-1.8610.477.46
2026-05-15NEO-1.8610.477.46
2026-05-18NEO-1.8614.387.46
2026-05-19NEO-1.8714.387.46
2026-05-20NEO-1.8714.387.46
2026-05-21NEO-1.8714.387.46
2026-05-22NEO-1.8714.387.46
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-0.06

Avg. EPS Est. Current Quarter

0.03

Avg. EPS Est. Next Quarter

0.05

Insider Transactions

-1.87

Institutional Transactions

14.38

Beta

1.79

Average Sales Estimate Current Quarter

196

Average Sales Estimate Next Quarter

205

Fair Value

Quality Score

43

Growth Score

43

Sentiment Score

97

Actual DrawDown %

83.2

Max Drawdown 5-Year %

-90.8

Target Price

15.06

P/E

Forward P/E

25.32

PEG

0.41

P/S

1.61

P/B

1.44

P/Free Cash Flow

EPS

-0.77

Average EPS Est. Cur. Y​

0.18

EPS Next Y. (Est.)

0.36

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-13.3

Relative Volume

0.4

Return on Equity vs Sector %

-39

Return on Equity vs Industry %

-22.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

NEO Healthcare
$9.23
📉
Swing / Pullback
Buy the dip on strong trends
59 /100
WATCH
Trend
14/20
Pullback
6/25
Volume
11/15
Valuation
15/20
TP/AR
5/10
Options
8/10
RSI
60.1
Range 1M
57.6%
Sup Dist
5.1%
🚀
Momentum Growth
Ride accelerating trends
N/A
53 /100
WEAK
Momentum
7/25
Growth
24/30
Estimates
8/20
Inst/Vol
6/15
Options
8/10
EPS Yr
50%
EPS NY
102.5%
52W%
49.8%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +44.1% upside
Quality
5/30
Valuation
15/30
Growth
19/25
Stability
8/10
LT Trend
1/5
Upside
+44.1%
Quality
43
NeoGenomics, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 2500
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
NEO

Latest News

Caricamento notizie per NEO
stock quote shares NEO – Neogenomics Inc. Stock Price stock today
news today NEO – Neogenomics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NEO – Neogenomics Inc. yahoo finance google finance
stock history NEO – Neogenomics Inc. invest stock market
stock prices NEO premarket after hours
ticker NEO fair value insiders trading

MYGN – Myriad Genetics, Inc.

MYGN — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

8.91

Margin Of Safety %

Put/Call OI Ratio

0.17

EPS Next Q Diff

0.23

EPS Last/This Y

4

EPS This/Next Y

0.11

Price

3.82

Target Price

6.38

Analyst Recom

2.9

Performance Q

-12.79

Upside

-4,058.1%

Beta

1.77

Ticker: MYGN




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-04-23MYGN4.780.46999.991559
2026-04-24MYGN4.770.500.111601
2026-04-27MYGN4.840.480.101661
2026-04-28MYGN4.840.470.501706
2026-04-29MYGN4.690.475.251706
2026-04-30MYGN4.730.480.001729
2026-05-01MYGN4.80.463.191787
2026-05-04MYGN4.930.380.001738
2026-05-05MYGN5.020.350.551836
2026-05-06MYGN4.110.390.521945
2026-05-07MYGN4.090.410.022202
2026-05-08MYGN4.280.410.182212
2026-05-11MYGN4.220.360.022124
2026-05-12MYGN4.070.360.022124
2026-05-13MYGN3.730.330.092201
2026-05-14MYGN3.620.320.082219
2026-05-15MYGN3.570.300.032217
2026-05-18MYGN3.640.180.001425
2026-05-19MYGN3.540.170.001523
2026-05-20MYGN3.810.170.001525
2026-05-21MYGN3.910.170.001526
2026-05-22MYGN3.820.170.391528
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-04-23MYGN4.79-129.8390.20.04
2026-04-24MYGN4.78-122.8390.20.05
2026-04-27MYGN4.84-122.8390.20.05
2026-04-28MYGN4.84-122.8390.30.05
2026-04-30MYGN4.74-122.8390.20.05
2026-05-01MYGN4.80-122.8390.20.05
2026-05-04MYGN4.93-122.8390.30.05
2026-05-05MYGN5.02-122.8390.50.05
2026-05-06MYGN4.10-122.8389.40.05
2026-05-07MYGN4.09-122.8- 0.05
2026-05-08MYGN4.29-122.8- 0.06
2026-05-11MYGN4.22-67.5- 0.06
2026-05-12MYGN4.07-67.5- 0.06
2026-05-13MYGN3.74-67.5- 0.06
2026-05-14MYGN3.63-67.5- 0.06
2026-05-15MYGN3.57-67.5- 0.06
2026-05-18MYGN3.64-175.6- 0.06
2026-05-19MYGN3.54-175.6- 0.06
2026-05-20MYGN3.81-175.6- 0.06
2026-05-21MYGN3.91-175.6- 0.05
2026-05-22MYGN3.82-220.0- 0.05
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-04-23MYGN2.32-5.6410.06
2026-04-24MYGN2.32-5.6410.06
2026-04-27MYGN2.32-5.329.46
2026-04-28MYGN2.32-5.329.46
2026-04-29MYGN2.32-5.329.46
2026-04-30MYGN2.32-5.329.46
2026-05-01MYGN2.32-5.329.46
2026-05-04MYGN2.32-5.409.46
2026-05-05MYGN2.32-5.409.46
2026-05-06MYGN2.32-5.409.46
2026-05-07MYGN2.32-5.409.46
2026-05-08MYGN2.32-5.409.45
2026-05-11MYGN2.31-5.909.36
2026-05-12MYGN2.31-5.908.95
2026-05-13MYGN2.31-5.908.95
2026-05-14MYGN2.31-5.908.95
2026-05-15MYGN2.44-5.908.95
2026-05-18MYGN2.44-10.018.90
2026-05-19MYGN2.65-10.018.90
2026-05-20MYGN2.65-10.018.90
2026-05-21MYGN2.65-10.018.91
2026-05-22MYGN2.59-10.018.91
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-0.16

Avg. EPS Est. Current Quarter

-0.06

Avg. EPS Est. Next Quarter

0.07

Insider Transactions

2.59

Institutional Transactions

-10.01

Beta

1.77

Average Sales Estimate Current Quarter

206

Average Sales Estimate Next Quarter

225

Fair Value

Quality Score

37

Growth Score

37

Sentiment Score

46

Actual DrawDown %

89.7

Max Drawdown 5-Year %

-90.3

Target Price

6.38

P/E

Forward P/E

23.87

PEG

0.35

P/S

0.44

P/B

1.07

P/Free Cash Flow

EPS

-4.32

Average EPS Est. Cur. Y​

0.05

EPS Next Y. (Est.)

0.16

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-48.24

Relative Volume

0.53

Return on Equity vs Sector %

-145.6

Return on Equity vs Industry %

-129.4

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.01

EBIT Estimation

MYGN Healthcare
$3.82
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
3/20
Pullback
23/25
Volume
11/15
Valuation
15/20
TP/AR
0/10
Options
8/10
RSI
39.7
Range 1M
17.9%
Sup Dist
1.6%
🚀
Momentum Growth
Ride accelerating trends
N/A
19 /100
WEAK
Momentum
1/25
Growth
10/30
Estimates
0/20
Inst/Vol
0/15
Options
8/10
EPS Yr
3.7%
EPS NY
157.1%
52W%
5.4%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +52.4% upside
Quality
6/30
Valuation
15/30
Growth
9/25
Stability
6/10
LT Trend
2/5
Upside
+52.4%
Quality
37
Myriad Genetics, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 2700
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
MYGN

Latest News

Caricamento notizie per MYGN
stock quote shares MYGN – Myriad Genetics, Inc. Stock Price stock today
news today MYGN – Myriad Genetics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MYGN – Myriad Genetics, Inc. yahoo finance google finance
stock history MYGN – Myriad Genetics, Inc. invest stock market
stock prices MYGN premarket after hours
ticker MYGN fair value insiders trading

MTD – Mettler-Toledo International, Inc.

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol= #%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]

stock_superchart: please set a ticker attribute.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

ticker required

Beta

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol= 589 360 ]

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol= 589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol= 589 450 ]
Sector:
Industry:
Employees:
[News_ _Stock]
stock quote shares MTD – Mettler-Toledo International, Inc. Stock Price stock today
news today MTD – Mettler-Toledo International, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MTD – Mettler-Toledo International, Inc. yahoo finance google finance
stock history MTD – Mettler-Toledo International, Inc. invest stock market
stock prices premarket after hours
ticker fair value insiders trading

GENE – Genetic Technologies Ltd. ADR

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=GENE #%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
GENE — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

0.76

Target Price

6.87

Analyst Recom

1

Performance Q

-14.99

Upside

N/A

Beta

1.11

Ticker: GENE




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-04-23GENE0.765N/AN/A0
2026-04-24GENE0.765N/AN/A0
2026-04-27GENE0.765N/AN/A0
2026-04-28GENE0.765N/AN/A0
2026-04-29GENE0.765N/AN/A0
2026-04-30GENE0.765N/AN/A0
2026-05-01GENE0.765N/AN/A0
2026-05-04GENE0.765N/AN/A0
2026-05-05GENE0.765N/AN/A0
2026-05-06GENE0.765N/AN/A0
2026-05-07GENE0.765N/AN/A0
2026-05-08GENE0.765N/AN/A0
2026-05-11GENE0.765N/AN/A0
2026-05-12GENE0.765N/AN/A0
2026-05-13GENE0.765N/AN/A0
2026-05-14GENE0.765N/AN/A0
2026-05-15GENE0.765N/AN/A0
2026-05-18GENE0.765N/AN/A0
2026-05-19GENE0.765N/AN/A0
2026-05-20GENE0.765N/AN/A0
2026-05-21GENE0.765N/AN/A0
2026-05-22GENE0.765N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




No data found




No data found

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=GENE 589 360 ]

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

1.11

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

30

Growth Score

29

Sentiment Score

7

Actual DrawDown %

98.5

Max Drawdown 5-Year %

-97.7

Target Price

6.87

P/E

Forward P/E

PEG

P/S

1.24

P/B

2.89

P/Free Cash Flow

EPS

-1.83

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-156.76

Relative Volume

Return on Equity vs Sector %

-680.2

Return on Equity vs Industry %

-667.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol=GENE 589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=GENE 589 450 ]
[News_GENE _Stock]
stock quote shares GENE – Genetic Technologies Ltd. ADR Stock Price stock today
news today GENE – Genetic Technologies Ltd. ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch GENE – Genetic Technologies Ltd. ADR yahoo finance google finance
stock history GENE – Genetic Technologies Ltd. ADR invest stock market
stock prices GENE premarket after hours
ticker GENE fair value insiders trading
No more stocks to show